BRPI0811478A2 - Compostos de morphinan - Google Patents

Compostos de morphinan

Info

Publication number
BRPI0811478A2
BRPI0811478A2 BRPI0811478-1A2A BRPI0811478A BRPI0811478A2 BR PI0811478 A2 BRPI0811478 A2 BR PI0811478A2 BR PI0811478 A BRPI0811478 A BR PI0811478A BR PI0811478 A2 BRPI0811478 A2 BR PI0811478A2
Authority
BR
Brazil
Prior art keywords
morphinan compounds
morphinan
compounds
Prior art date
Application number
BRPI0811478-1A2A
Other languages
English (en)
Inventor
Robert Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Priority claimed from PCT/US2008/062089 external-priority patent/WO2008137474A1/en
Publication of BRPI0811478A2 publication Critical patent/BRPI0811478A2/pt
Publication of BRPI0811478A8 publication Critical patent/BRPI0811478A8/pt
Publication of BRPI0811478B1 publication Critical patent/BRPI0811478B1/pt
Publication of BRPI0811478B8 publication Critical patent/BRPI0811478B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/491—Blood by separating the blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
BRPI0811478A 2007-05-01 2008-04-30 compostos de morfinano, composição contendo os ditos compostos, usos dos mesmos, embalagem e formas de dosagem separadas BRPI0811478B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US91513007P 2007-05-01 2007-05-01
US60/915,130 2007-05-01
US91666207P 2007-05-08 2007-05-08
US60/916,662 2007-05-08
US97604407P 2007-09-28 2007-09-28
US60/976,004 2007-09-28
PCT/US2008/062089 WO2008137474A1 (en) 2007-05-01 2008-04-30 Morphinan compounds

Publications (4)

Publication Number Publication Date
BRPI0811478A2 true BRPI0811478A2 (pt) 2014-11-04
BRPI0811478A8 BRPI0811478A8 (pt) 2019-10-15
BRPI0811478B1 BRPI0811478B1 (pt) 2020-12-29
BRPI0811478B8 BRPI0811478B8 (pt) 2021-05-25

Family

ID=51894365

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811478A BRPI0811478B8 (pt) 2007-05-01 2008-04-30 compostos de morfinano, composição contendo os ditos compostos, usos dos mesmos, embalagem e formas de dosagem separadas

Country Status (15)

Country Link
US (6) US9314440B2 (pt)
EP (5) EP2792662B1 (pt)
BR (1) BRPI0811478B8 (pt)
CA (3) CA3056205C (pt)
CY (1) CY1117826T1 (pt)
DK (4) DK2522668T3 (pt)
ES (5) ES2951028T3 (pt)
FI (1) FI3825306T3 (pt)
HK (5) HK1178889A1 (pt)
HR (5) HRP20230745T3 (pt)
HU (3) HUE029782T2 (pt)
LT (1) LT3825306T (pt)
PL (3) PL2357183T3 (pt)
PT (5) PT2357183E (pt)
SI (2) SI3825306T1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632916B1 (en) * 2007-05-01 2022-06-08 Concert Pharmaceuticals Inc. Morphinan compounds
FI3825306T3 (fi) 2007-05-01 2023-08-23 Concert Pharmaceuticals Inc Morfinaaniyhdisteitä
WO2017020002A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
US20180243291A1 (en) * 2015-07-30 2018-08-30 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for treating agitation
JP6694216B2 (ja) 2015-10-14 2020-05-13 学校法人 久留米大学 グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤
AU2018210230A1 (en) * 2017-01-19 2019-09-05 Donald Danforth Plant Science Center Morphinan N-demethylase isolated from the Methylobacterium Thebainfresser and methods of use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US38115A (en) 1863-04-07 Improvement in turning edges of plates or metal sheets
GB713146A (en) 1951-10-18 1954-08-04 Roche Products Ltd Anti-cough agents comprising (ú½)-3-hydroxy-n-methyl-morphinane ethers and process for the manufacture thereof
US4316888A (en) 1980-04-15 1982-02-23 Nelson Research & Development Co. Method and composition of reducing pain
US4446140A (en) 1981-12-10 1984-05-01 Nelson Research & Development Company Method and composition for treating mouth pain
JPS6089474A (ja) 1983-10-20 1985-05-20 Toyo Pharma- Kk モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
US4694010A (en) 1985-08-16 1987-09-15 New York University Anticonvulsant compositions and method
US4898860A (en) 1985-08-16 1990-02-06 New York University Anticonvulsant composition and method
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US5336980A (en) 1992-12-10 1994-08-09 Leopold Kostal Gmbh & Co. Apparatus and method for controlling a windshield wiping system
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
USRE38115E1 (en) 1994-09-22 2003-05-06 Center For Neurologic Study Dextromethorphan and an oxidase inhibitor for treating intractable conditions
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6197830B1 (en) 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CH690817A5 (de) 1996-09-03 2001-01-31 Flachsmann Ag Emil Verfahren zur Herstellung eines stabilen, homogenen, von Folgeprodukten freien oder nahezu freien Extraktes.
CN1150196C (zh) 1997-03-27 2004-05-19 东丽株式会社 吗啡烷衍生物及医药用途
US6884429B2 (en) 1997-09-05 2005-04-26 Isotechnika International Inc. Medical devices incorporating deuterated rapamycin for controlled delivery thereof
EP1051163A2 (en) 1998-01-29 2000-11-15 Sepracor, Inc. Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PT1104760E (pt) 1999-12-03 2003-06-30 Pfizer Prod Inc Compostos de sulfamoil-heteroarilpirazole como agentes analgesicos e anti-inflamatorios
AU4517201A (en) 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US20050129783A1 (en) 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US6780871B2 (en) 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
US6583152B2 (en) 2001-04-30 2003-06-24 Dexgen Pharmaceuticals, Inc. Composition for reducing the risk or progression of cardiovascular diseases
US20040087479A1 (en) 2001-04-30 2004-05-06 Sosnowski Robert E. Composition and method for reducing the risk or progression of cardiovascular, glaucoma, tardive dyskinesia and other diseases
JP4101661B2 (ja) 2001-05-03 2008-06-18 エフ．ホフマン−ラ ロシュ アーゲー 非晶質メシル酸ネルフィナビルの製薬剤形
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
UA77234C2 (en) 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
EP2987788A1 (en) 2002-05-17 2016-02-24 Taiwanj Pharmaceuticals Co., Ltd. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE102004009445A1 (de) 2004-02-27 2005-09-29 Chemetall Gmbh Verfahren zur Herstellung von Alkyllithiumverbindungen und Aryllithiumverbindungen durch Reaktionsverfolgung mittels IR-Spektroskopie
WO2005110412A1 (en) 2004-05-14 2005-11-24 Green Cross Corp. Neuroprotective properties of dextrorotatory morphinans
CA2581169A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
US20070191411A1 (en) 2004-10-07 2007-08-16 Smith Richard A Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor
US7114547B2 (en) 2005-01-11 2006-10-03 Sullivan Michael R Casting ring
JP5289951B2 (ja) 2005-07-26 2013-09-11 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング 同位体置換されたパントプラゾール
KR101380190B1 (ko) 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
BRPI0714484A2 (pt) 2006-08-16 2013-04-24 Auspex Pharmaceuticals Inc composto, mÉtodo de tratar um mamÍfero sofrendo de uma doenÇa ou condiÇço, mÉtodo de tratar um memÍfero sofrendo de uma doenÇa, desordem, sintoma ou condiÇço e composiÇço farmacÊutica
JP2010502702A (ja) 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
WO2008097924A2 (en) 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
CN101687868B (zh) 2007-05-01 2012-12-12 康塞特医药品公司 吗啡烷化合物
FI3825306T3 (fi) 2007-05-01 2023-08-23 Concert Pharmaceuticals Inc Morfinaaniyhdisteitä
BRPI0918760A2 (pt) 2008-09-19 2015-12-29 Concert Pharmaceuticals Inc compostos morfinanos
EP3090760A1 (en) 2008-10-30 2016-11-09 Concert Pharmaceuticals, Inc. Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury
JP6525419B2 (ja) 2015-01-15 2019-06-05 株式会社半導体エネルギー研究所 二次電池

Also Published As

Publication number Publication date
FI3825306T3 (fi) 2023-08-23
CA3208128A1 (en) 2008-11-13
HRP20150809T1 (hr) 2016-02-12
EP3093290A1 (en) 2016-11-16
PT2522667E (pt) 2014-11-11
PL2792662T3 (pl) 2016-10-31
EP3093290B1 (en) 2018-01-24
US20140329846A1 (en) 2014-11-06
EP2357183B1 (en) 2015-07-01
US20240117407A1 (en) 2024-04-11
HK1259133A1 (zh) 2019-11-29
BRPI0811478A8 (pt) 2019-10-15
DK3825306T3 (da) 2023-09-11
HRP20150848T1 (hr) 2015-09-25
HRP20230745T3 (hr) 2023-10-27
US20210348208A1 (en) 2021-11-11
EP3357923A1 (en) 2018-08-08
US9314440B2 (en) 2016-04-19
HRP20160521T8 (hr) 2016-10-07
HUE029782T2 (en) 2017-04-28
PL2357183T3 (pl) 2015-12-31
DK2522668T3 (en) 2015-05-26
EP3825306B1 (en) 2023-06-07
PT2792662T (pt) 2016-07-07
HK1155442A1 (en) 2012-05-18
ES2523286T3 (es) 2014-11-24
EP2357183A1 (en) 2011-08-17
US20240093265A1 (en) 2024-03-21
BRPI0811478B1 (pt) 2020-12-29
HRP20160521T1 (hr) 2016-08-12
ES2951028T3 (es) 2023-10-17
CA3056205A1 (en) 2008-11-13
HUE063526T2 (hu) 2024-01-28
HK1178889A1 (en) 2013-09-19
DK2357183T3 (en) 2015-09-07
SI3825306T1 (sl) 2023-10-30
EP3825306A1 (en) 2021-05-26
SI2792662T1 (sl) 2016-10-28
HUE025569T2 (en) 2016-02-29
PT2357183E (pt) 2015-09-28
CA2945581C (en) 2021-11-16
CA3056205C (en) 2023-09-26
EP3825306B8 (en) 2023-08-02
ES2536984T3 (es) 2015-06-01
US11473123B2 (en) 2022-10-18
ES2577477T3 (es) 2016-07-15
CA2945581A1 (en) 2008-11-13
PL3825306T3 (pl) 2023-09-11
DK2792662T3 (da) 2016-07-25
US20180327809A1 (en) 2018-11-15
EP2792662A1 (en) 2014-10-22
HK1178154A1 (en) 2013-09-06
US20170037449A1 (en) 2017-02-09
EP2792662B1 (en) 2016-04-06
PT2522668E (pt) 2015-06-09
CY1117826T1 (el) 2017-05-17
HK1201058A1 (zh) 2015-08-21
US9868976B2 (en) 2018-01-16
ES2545617T3 (es) 2015-09-14
HRP20140903T1 (hr) 2014-11-21
BRPI0811478B8 (pt) 2021-05-25
PT3825306T (pt) 2023-07-24
EP3357923B1 (en) 2019-11-13
LT3825306T (lt) 2023-08-10

Similar Documents

Publication Publication Date Title
BRPI0918760A2 (pt) compostos morfinanos
BRPI0815042A2 (pt) Compostos de pirazol
BRPI0815067A2 (pt) Compostos de biciclotactama substituída
BRPI0813500A2 (pt) Compostos antivirais
BRPI0821086A2 (pt) Compostos inseticidas
BRPI0818380A2 (pt) Combinação de herbicida-protetor
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0817935A2 (pt) Derivados de biarila
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0811264A2 (pt) Compostos
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0810926A2 (pt) Antagonista de crig
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0814718A2 (pt) Derivados de isoxazol-imidazol
BRPI0809996A2 (pt) Compostos
HK1259133A1 (zh) 嗎啡烷化合物
BRPI0815181A2 (pt) Compostos
BRPI0911393A2 (pt) composto de 5-hidroxipirimidina-4-carboxamida
BRPI0811214A2 (pt) Derivados de pirazolona
BRPI0812827A2 (pt) Derivados de macrolactona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: FOI SOLICITADA NA PETICAO NO 020110005651 A RETIFICACAO DA PRIORIDADE US 60/976,044 QUE TERIA SIDO ALVO DE ERRO MATERIAL DURANTE A FASE INTERNACIONAL DO PEDIDO. TENDO EM VISTA A VEROSSIMILHANCA DA ALEGACAO E A APRESENTACAO DE TODO O PEDIDO PRIORITARIO CORRETO NA PETICAO NO 870160039608, SERA DEFERIDA A ALTERACAO. NO ENTANTO, NOS DOCUMENTOS DE CESSAO APRESENTADOS NA PETICAO NO 020090121950, NAO CONSTAM A CESSAO DO DIREITO DE PRIORIDADE DA PRIORIDADE CORRETA, E SIM DA QUE FOI ALVO DE ERRO MATERIAL. REGULARIZE A CESSAO DA PRIORIDADE US 60/976,044, JA QUE O DOCUMENTO APRESENTADO NAO FAZ MENCAO A TAL PRIORIDADE, SOB PENA DE PERDA DA PRIORIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF